Pharmacogenetics and pharmacogenomics of anticancer agents

R. Stephanie Huang, Mark J. Ratain

Research output: Contribution to journalReview articlepeer-review

101 Scopus citations

Abstract

Large interindividual variation is observed in both the response and toxicity associated with anticancer therapy. The etiology of this variation is multifactorial, but is due in part to host genetic variations. Pharmacogenetic and pharmacogenomic studies have successfully identified genetic variants that contribute to this variation in susceptibility to chemotherapy. This review provides an overview of the progress made in the field of pharmacogenetics and pharmacogenomics using a five-stage architecture, which includes 1) determining the role of genetics in drug response; 2) screening and identifying genetic markers; 3) validating genetic markers; 4) clinical utility assessment; and 5) pharmacoeconomic impact. Examples are provided to illustrate the identification, validation, utility, and challenges of these pharmacogenetic and pharmacogenomic markers, with the focus on the current application of this knowledge in cancer therapy. With the advance of technology, it becomes feasible to evaluate the human genome in a relatively inexpensive and efficient manner; however, extensive pharmacogenetic research and education are urgently needed to improve the translation of pharmacogenetic concepts from bench to bedside.

Original languageEnglish (US)
Pages (from-to)42-55
Number of pages14
JournalCA Cancer Journal for Clinicians
Volume59
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint Dive into the research topics of 'Pharmacogenetics and pharmacogenomics of anticancer agents'. Together they form a unique fingerprint.

Cite this